Cargando…

Seven-year follow-up of percutaneous closure of patent foramen ovale()

BACKGROUND: Observational studies favor percutaneous closure of patent foramen ovale (PFO) over medical treatment to reduce recurrent stroke while randomized trials fail to demonstrate significant superiority of percutaneous PFO closure. Few long-term studies are available post PFO closure. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirzada, Naqibullah, Ladenvall, Per, Hansson, Per-Olof, Johansson, Magnus Carl, Furenäs, Eva, Eriksson, Peter, Dellborg, Mikael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801002/
https://www.ncbi.nlm.nih.gov/pubmed/29450155
http://dx.doi.org/10.1016/j.ijchv.2013.11.003
_version_ 1783298282029580288
author Mirzada, Naqibullah
Ladenvall, Per
Hansson, Per-Olof
Johansson, Magnus Carl
Furenäs, Eva
Eriksson, Peter
Dellborg, Mikael
author_facet Mirzada, Naqibullah
Ladenvall, Per
Hansson, Per-Olof
Johansson, Magnus Carl
Furenäs, Eva
Eriksson, Peter
Dellborg, Mikael
author_sort Mirzada, Naqibullah
collection PubMed
description BACKGROUND: Observational studies favor percutaneous closure of patent foramen ovale (PFO) over medical treatment to reduce recurrent stroke while randomized trials fail to demonstrate significant superiority of percutaneous PFO closure. Few long-term studies are available post PFO closure. This study reports long-term clinical outcomes after percutaneous PFO closure. METHODS: Between 1997 and 2006, 86 consecutive eligible patients with cerebrovascular events, presumably related to PFO, underwent percutaneous PFO closure. All 86 patients were invited to a long-term follow-up, which was carried out during 2011 and 2012. RESULTS: Percutaneous PFO closure was successfully performed in 85 of 86 patients. The follow-up rate was 100%. No cardiovascular or cerebrovascular deaths occurred. Two patients (both women) died from lung cancer during follow-up. Follow-up visits were conducted for 64 patients and the remaining 20 patients were followed up by phone. The mean follow-up time was 7.3 years (5 to 12.4 years). Mean age at PFO closure was 49 years. One patient had a minor stroke one month after PFO closure and a transient ischemic attack (TIA) two years afterwards. One other patient suffered from a TIA six years after closure. No long-term device-related complications were observed. CONCLUSIONS: Percutaneous PFO closure was associated with very low risk of recurrent stroke and is suitable in most patients. We observed no mortality and no long-term device-related complications related to PFO closure, indicating that percutaneous PFO closure is a safe and efficient treatment even in the long term.
format Online
Article
Text
id pubmed-5801002
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-58010022018-02-15 Seven-year follow-up of percutaneous closure of patent foramen ovale() Mirzada, Naqibullah Ladenvall, Per Hansson, Per-Olof Johansson, Magnus Carl Furenäs, Eva Eriksson, Peter Dellborg, Mikael Int J Cardiol Heart Vessel Article BACKGROUND: Observational studies favor percutaneous closure of patent foramen ovale (PFO) over medical treatment to reduce recurrent stroke while randomized trials fail to demonstrate significant superiority of percutaneous PFO closure. Few long-term studies are available post PFO closure. This study reports long-term clinical outcomes after percutaneous PFO closure. METHODS: Between 1997 and 2006, 86 consecutive eligible patients with cerebrovascular events, presumably related to PFO, underwent percutaneous PFO closure. All 86 patients were invited to a long-term follow-up, which was carried out during 2011 and 2012. RESULTS: Percutaneous PFO closure was successfully performed in 85 of 86 patients. The follow-up rate was 100%. No cardiovascular or cerebrovascular deaths occurred. Two patients (both women) died from lung cancer during follow-up. Follow-up visits were conducted for 64 patients and the remaining 20 patients were followed up by phone. The mean follow-up time was 7.3 years (5 to 12.4 years). Mean age at PFO closure was 49 years. One patient had a minor stroke one month after PFO closure and a transient ischemic attack (TIA) two years afterwards. One other patient suffered from a TIA six years after closure. No long-term device-related complications were observed. CONCLUSIONS: Percutaneous PFO closure was associated with very low risk of recurrent stroke and is suitable in most patients. We observed no mortality and no long-term device-related complications related to PFO closure, indicating that percutaneous PFO closure is a safe and efficient treatment even in the long term. Elsevier 2013-11-14 /pmc/articles/PMC5801002/ /pubmed/29450155 http://dx.doi.org/10.1016/j.ijchv.2013.11.003 Text en © 2013 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Article
Mirzada, Naqibullah
Ladenvall, Per
Hansson, Per-Olof
Johansson, Magnus Carl
Furenäs, Eva
Eriksson, Peter
Dellborg, Mikael
Seven-year follow-up of percutaneous closure of patent foramen ovale()
title Seven-year follow-up of percutaneous closure of patent foramen ovale()
title_full Seven-year follow-up of percutaneous closure of patent foramen ovale()
title_fullStr Seven-year follow-up of percutaneous closure of patent foramen ovale()
title_full_unstemmed Seven-year follow-up of percutaneous closure of patent foramen ovale()
title_short Seven-year follow-up of percutaneous closure of patent foramen ovale()
title_sort seven-year follow-up of percutaneous closure of patent foramen ovale()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801002/
https://www.ncbi.nlm.nih.gov/pubmed/29450155
http://dx.doi.org/10.1016/j.ijchv.2013.11.003
work_keys_str_mv AT mirzadanaqibullah sevenyearfollowupofpercutaneousclosureofpatentforamenovale
AT ladenvallper sevenyearfollowupofpercutaneousclosureofpatentforamenovale
AT hanssonperolof sevenyearfollowupofpercutaneousclosureofpatentforamenovale
AT johanssonmagnuscarl sevenyearfollowupofpercutaneousclosureofpatentforamenovale
AT furenaseva sevenyearfollowupofpercutaneousclosureofpatentforamenovale
AT erikssonpeter sevenyearfollowupofpercutaneousclosureofpatentforamenovale
AT dellborgmikael sevenyearfollowupofpercutaneousclosureofpatentforamenovale